Search Results - "AVRAMIS, V. I"

Structure-function relationships and clinical applications of L-asparaginases by Labrou, N E, Papageorgiou, A C, Avramis, V I

“…L-asparaginase (L-ASNase, EC 3.5.1.1) catalyzes the hydrolysis of the non-essential amino acid L-Asn to LAsp and ammonia and is widely used for the treatment…”
Get more information

Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation by Villablanca, J G, Khan, A A, Avramis, V I, Seeger, R C, Matthay, K K, Ramsay, N K, Reynolds, C P

“…Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation. Since cis-RA has demonstrated…”
Get more information

Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines by Avramis, I A, Kwock, R, Avramis, V I

“…Recent studies have shown that angiogenesis, which is induced by VEGF, may be involved in the pathogenesis of hematopoietic malignancies. A human leukemia…”
Get more information

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group by Dinndorf, P A, Avramis, V I, Wiersma, S, Krailo, M D, Liu-Mares, W, Seibel, N L, Sato, J K, Mosher, R B, Kelleher, J F, Reaman, G H

“…The Children's Cancer Group (CCG) undertook a phase I study (CCG-0922) to determine a tolerable dose of idarubicin given with fludarabine and cytarabine in…”
Get more information

NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias by PERICLOU, A. P, AVRAMIS, V. I

“…We examined the population pharmacokinetics (PPK) of cytosine arabinoside (ara-C) after high-dose ara-C (HDara-C) (3 g/m2 every 12 h) and after a loading bolus…”
Get full text

Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells by Avramis, V I, Nandy, P, Kwock, R, Solorzano, M M, Mukherjee, S K, Danenberg, P, Cohen, L J

“…Combinations of nucleoside analog drugs, such as F-araA and ara-C, combined with Topoisomerase II inhibitors, such as anthracyclines, are synergistic against…”
Get more information

Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside by MESSINGER, Y, YANISHEVSKI, Y, AVRAMIS, V. I, EK, O, CHELSTROM, L. M, GUNTHER, R, MYERS, D. E, IRVIN, J. D, EVANS, W, UCKUN, F. M

“…Combined immunochemotherapy regimens using the investigational biotherapeutic agent B43(anti-CD19)-poke-weed antiviral protein (PAP) immunotoxin may offer an…”
Get full text

Biochemical pharmacology and DNA methylation studies of arabinosyl 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell lines PER-145 and PER-163 by Kees, U R, Avramis, V I

“…1-beta-D-arabinofuranosyl-5-azacytosine (ara-AC) and 5,6-dihydro-5-azacytidine (DHAC) are two new antitumor agents under clinical investigations, which exhibit…”
Get more information

Protein phosphatase 1α-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein by WANG, Rui-Hong, LIU, Cathy W. Y, AVRAMIS, Vassilios I, BERNDT, Norbert

“…Protein phosphatase 1 (PP1) plays important roles in many different aspects of cellular activities including cell cycle control. One important function of PP1…”
Get full text

Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM) by Avramis, V I, Markson, W, Jackson, R L, Gomperts, E

“…HIV is the causative agent of AIDS. The purpose of this study was to examine the biochemical pharmacology of the anti-viral agent zidovudine (AZT) in the…”
Get more information

Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis by Nandy, P, Lien, E J, Avramis, V I

“…The hydroxyisoindole dione derivatives ISID and MISID are new compounds with structures resembling purines and possessing a hydroxamic acid moiety which is the…”
Get more information

Phase I Study of Gemcitabine (Difluorodeoxycytidine) in Children with Relapsed or Refractory Leukemia (CCG-0955): A Report from the Children's Cancer Group by Steinherz, P.G., Seibel, N.L., Ames, M.M., Avramis, V.I., Krailo, M.D., Liu-Mares, W., Reid, J.M., Safgren, S.L., Reaman, G.H.

“…To determine the maximum tolerated dose (MTD) and assess the toxicity profile and pharmacokinetics of weekly gemcitabine infusions in pediatric patients with…”
Get full text

The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines by Majlessipour, F, Avramis, I A, Kwock, R, Weinberg, K I, Avrami, V I

“…Up-regulation of Bcl-2 protein may contribute to drug resistance, by decreasing apoptosis after treatment, in pre-B and B-cell leukemias in pediatric patients…”
Get more information

Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation by KHAN, A. A, VILLABLANCA, J. G, REYNOLDS, C. P, AVRAMIS, V. I

“…A phase I clinical trial of 13-cis-retinoic acid (cis-RA) was undertaken to determine the maximally tolerated dose (MTD) and pharmacokinetics (PK) of cis-RA…”
Get full text

Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs by Martin-Aragon, S, Mukherjee, S K, Taylor, B J, Ivy, S P, Fu, C H, Ardi, V C, Avramis, V I

“…The major limitation of treatment with antimetabolite drugs is that they produce resistant clones both in vitro and in patients who either do not respond to…”
Get more information

Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities by Majlessipour, F, Kwock, R, Martin-Aragon, S, Weinberg, K I, Avramis, V I

“…We have developed an in vitro model of 38 T-lymphoblastic leukemia lines resistant to cytosine arabinoside (ara-C) and L-asparaginase (ASNase). Of these, 26…”
Get more information

Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein by FU, Cecilia H, MARTIN-ARAGON, Sagrario, WEINBERG, Kenneth I, ARDI, Veronica C, DANENBERG, Peter V, AVRAMIS, Vassilios I

“…Sequence-specific combinations of purine analogs, such as fludarabine or 6-mercaptopurine (6-MP), administered prior to cytosine arabinoside (ara-C) have been…”
Get full text

Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection by Avramis, V I, Kwock, R, Solorzano, M M, Gomperts, E

“…Clinical reports indicate that the development of drug resistance to AZT after chronic administration is common. In order to study this phenomenon, the T-cell…”
Get more information

Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma by Avramis, V I, Kwock, R, Avramis, I A, Cohen, L J, Inderlied, C

“…We evaluated the anti-HIV-1 activity of the T-cell-specific protein inhibitor PEG-asparaginase (PEG-ASNase) in human HIV-1-infected T-cells. We further…”
Get more information

Synthesis and testing of new antileukemic schiff bases of N-hydroxy-N'-aminoguanidine against CCRF-CEM/0 human leukemia cells in vitro and synergism studies with cytarabine (Ara-C) by KONERU, P. B, LIEN, E. J, AVRAMIS, V. I

“…A series of eight new N-hydroxy-N'-aminoguanidine (HAG) Schiff bases [ArCH = NNHC(= NH)NHOH.tosylate] was synthesized as potential antitumor agents through the…”
Get full text